Close menu

Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the appointment of Mathieu-William Gilbert as Chief Operating Officer (COO).



Mathieu joins Adocia after serving as Vice-President Strategic Projects of International Commercial Operations at Novo Nordisk. Prior to this, he held the position of Vice President & General Manager of six Latin American countries, with responsibility for all Novo Nordisk activities in the region, as well as the establishment of the Obesity franchise and the commercial launch of Ozempic®.


Read the press release

More information